Matritech Triples Sales Force To Drive U.S. BladderChek Sales
This article was originally published in The Gray Sheet
Executive Summary
Matritech expects that its U.S. marketing strategy for NMP22 BladderChek - solely using its internal sales force to target urologists - will improve 2004 revenue
You may also be interested in...
Financings In Brief
Cutera IPO: CoolGlide aesthetic laser manufacturer will use $15 mil. of the expected $38.7 mil. in net proceeds to expand its 40-person sales & marketing team, according to a March 30 1prospectus filed with SEC. Roughly $5 mil. is earmarked for R&D, and the rest will go to "general corporate purposes." Piper Jaffray is lead underwriter for the IPO, which is offering 3.5 mil. shares of Cutera common stock at $14; SG Cowen and RBC Capital Markets are co-managers. The firm intends to trade on Nasdaq under the symbol "CUTR." Cutera, formerly Altus Medical, first filed to go public in January 2002, but later abandoned the attempt (2"The Gray Sheet" Jan. 28, 2002, p. 17). In Q1 alone, other device and diagnostic firms opting to go public included Digirad, Immunicon, NuVasive, Angiodynamics, Kinetic Concepts, Animus and Novacept...
Financings In Brief
Cutera IPO: CoolGlide aesthetic laser manufacturer will use $15 mil. of the expected $38.7 mil. in net proceeds to expand its 40-person sales & marketing team, according to a March 30 1prospectus filed with SEC. Roughly $5 mil. is earmarked for R&D, and the rest will go to "general corporate purposes." Piper Jaffray is lead underwriter for the IPO, which is offering 3.5 mil. shares of Cutera common stock at $14; SG Cowen and RBC Capital Markets are co-managers. The firm intends to trade on Nasdaq under the symbol "CUTR." Cutera, formerly Altus Medical, first filed to go public in January 2002, but later abandoned the attempt (2"The Gray Sheet" Jan. 28, 2002, p. 17). In Q1 alone, other device and diagnostic firms opting to go public included Digirad, Immunicon, NuVasive, Angiodynamics, Kinetic Concepts, Animus and Novacept...
Roche Amplicor HPV Test To Battle With Digene: A David & Goliath Scenario?
Roche Diagnostics' plan to obtain a CE mark by the second quarter for its Amplicor human papillomavirus PCR-based test and complete U.S. trials by Q2 2005 has Digene scurrying to maintain its DNAwithPap first-to-market advantage